Abstract
Female B6C3F1 mice (12–14 weeks old) were dosed with busulphan (BU) by the intraperitoneal route at a range of dose levels between 10 and 40 mg/kg on four occasions at 14 day intervals. Six weeks after the final dose, mice were given normal drinking water or drinking water containing chloramphenicol succinate (CAP.S) at 4 mg/ml. Animals were killed at eight timepoints after the final BU dose, the final samples being taken at day 485 or 497. A range of haematological parameters were determined and lymphocyte subsets analysed. The inclusion of CAP.S in the drinking water did not affect the changes to haematological parameters or lymphocyte subsets induced by BU. Lymphocyte count was reduced to 51%–66% of control values in animals receiving 40 mg BU/kg on all occasions except day 85. However, the lymphocyte count was increased to 107%–143% of control values in animals receiving 10 mg BU/kg on all occasions except day 85. The large unstained cell (LUC) count was reduced to between 25%–47% of control values in animals receiving 40 mg BU/kg on all occasions, however, the LUC count was not increased at low BU dosage. At day 485/497, B lymphocyte counts were reduced to 48% (p<0.01), 64% (NS) and 55% (p<0.05) of control values in mice treated with 40, 33 and 25 mg BU/kg, respectively. T lymphocyte counts were not affected by BU treatment. We have, therefore, demonstrated in the present study that administration of BU at high levels to the B6C3F1 mouse induces a long-lasting and specific depletion of peripheral B lymphocytes; also, BU at low dose levels causes a mild but persistent lymphocytosis.
Similar content being viewed by others
References
Addison IE (1973) Immunosuppression with busulphan: the effect on spleen, marrow and thymus cells of mice. Eur J Immunol 3:419–424
Andrews CM, Spurting NW, Turton JA (1993) Characterisation of busulphan-induced myelotoxicity in B6C3F1 mice using flow cytometry. Comp Haematol Int 3: 102–115
Beutler E, Lichtman MA, Coller BS et al. (eds) (1995) Williams’ hematology, (5th edn). McGraw-Hill, New York
Bhoopalam N, Price KS, Norgello H et al. (1985) Busulfan-induced suppression of natural killer activity. Exp Hematol 13:1127–1132
Boggs DR, Boggs SS (1980) The effect of graded, single doses of busulfan on murine erythropoiesis. Proc Soc Exp Biol Med 163:181–186
Borella L, Green AA, Webster RG (1972) Immunologic rebound after cessation of long-term chemotherapy in acute leukaemia. Blood 40:42–51
Braun DP, Harris JE (1981) Modulation of the immune response by chemotherapy. Pharmacol Ther 14:89–122
Brohee D, Neve P, Vanhaeverbeek M et al. (1991) Is lymphopenia an obligatory side effect of all cancer chemotherapy treatments? Med Sci Res 19:801–802
den Ottolander GJ, te Velde J, Veenhof W et al. (1982) Busulphan aplasia in rabbits: a model for human aplastic anaemia. Br J Haematol 51: 265–276
Dunn CDR (1974) The chemical and biological properties of busulphan (‘myeleran’). Exp Hematol 2:101–117
Elson LA (1955) A comparison of the effects of radiation and radiomimetic chemicals on the blood. Br J Haematol 1:104–116
Elson LA, Galton DAG, Till M (1958) The action of chlorambucil and busulphan on the haemopoietic organs of the rat. Br J Haematol 4:355–374
Fitchen JH, Cline MJ (1980) The effect of granulopoietic stress in mice with ‘latent’ bone marrow failure. Exp Hematol 8:788–794
Gascon P, Zoumbous N, Young N (1986) Analysis of natural killer cells in patients with aplastic anaemia. Blood 67:1349–1355
Hall AG, Tilby MJ (1992) Mechanisms of actions of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 6:163–173
Irons RD, Stillman WS (1993) Cell proliferation and differentiation in chemical leukemogenesis. Stem Cells 11:235–242
Kato T, Ohta Y, Suzumura Y et al. (1988) Antitumour activity and neutrophil-selective hematopoietic toxicity of busulphan analogs in mice. Jpn J Cancer Res 79:1048–1053
Kinsey SE, Watts MJ (1988) Accurate automated leucocyte differential counts despite profound leucopenia. J Clin Pathol 41:1236–1239
Koza I, Babusikova O (1988) Sequential development of chronic lymphocytic leukaemia in a patient with polycythaemia vera. Neoplasma 35:77–80
Miale TD, Bloom GE (1975) The significance of lymphocytosis in congenital hypoplastic anemia. J Pediatr 87:550–553
Mitchell MS (1988) Combining chemotherapy with biological response modifiers in treatment of cancer. J Natl Cancer Inst 80:1445–1450
Morley A, Blake J (1974a) An animal model of chronic hypoplastic marrow failure. I. Late marrow failure after busulfan. Blood 44:49–56
Morley A, Blake J (1974b) Haemopoietic precursor cells in experimental hypolplastic marrow failure. Aust J Exp Biol Med Sci 52:909–914
Morley A, Holmes K, Forbes I (1974) Depletion of B lymphocytes in chronic hypoplastic marrow failure (aplastic anaermia). Aust NZ J Med 4:538–541
Morley A, Trainor K, Blake J (1975) A primary stem cell lesion in experimental chronic hypoplastic marrow failure. Blood 45:681–688
Morley A, Trainor K, Remes J (1976) Residual marrow damage: possible explanation for idiosyncrasy to chloramphenicol. Br J Haematol 32:525–531
Papayannis AG, Nikiforakis E, Aanagnostou-Keramida D (1982) Development of chronic lymphocytic leukaemia in a patient with polycythaemia vera. Scand J Haematol 29:65–69
Pugsley CAJ, Forbes IJ, Morley AA (1978) Immulogic abnormalities in an animal model of chronic hypoplastic marrow failure induced by busulfan. Blood 51:601–610
Robin E, Berman M, Bhoopalam N et al. (1981) Induction of lymphomas in mice by busulfan and chloramphenicol. Cancer Res 41:3478–3842
Sabbe LJM, Haak HL, Te Velde J et al. (1984) Immunlogical investigations in aplastic anaemia. Acta Haematol 71:178–188
Santos GW, Tutschka PJ (1974) Marrow transplantation in the busulfan-treated rat; preclinal model of aplastic anemia. J Natl Cancer Inst 53:1781–1785
Tonner E, Sewell HF, Thomson AW (1988) Cancer-induced alterations in T-cell subsets in normal and cyclophosphamide-treated mice. Int Arch Appl Immund 85:180–183
Vincent PC (1986) Drug-induced aplastic anaemia and agranulocytosis: incidence and mechanisms. Drugs 31:52–63
Wathen LM, DeGowin RL, Gibson P et al. (1982) Residual injury to the hemopoietic microenvironment following sequential radiation and busulfan. Int J Radiat Oncol Biol Phys 8:1315–1322
Yeager AM, Shinn C, Pardoll DM (1991) Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice. Blood 78:12 3312–3316
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Andrews, C.M., Dash, L.M., Williams, T.C. et al. Long-term effects of busulphan on lymphocyte subpopulations in female B6C3F1 mice. Comparative Haematology International 7, 230–237 (1997). https://doi.org/10.1007/BF02658695
Issue Date:
DOI: https://doi.org/10.1007/BF02658695